(E,2R)-2-methyl-4-thiophen-2-ylbut-3-en-1-ol | 145037-63-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 杂芳族化合物
• 英文名称: (E,2R)-2-methyl-4-thiophen-2-ylbut-3-en-1-ol
• CAS: 145037-63-4
• 化学式: C₉H₁₂OS
• 分子量: 168.26
• InChiKey: MAUHDLSJFORXOF-WTSVBCDHSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  11
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  48.5
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  (E,2R)-2-methyl-4-thiophen-2-ylbut-3-en-1-ol 在 咪唑 、 正丁基锂 作用下， 以 二氯甲烷 为溶剂， 反应 1.67h， 生成 (R)-ethyl 5-<1-(tert-butyldimethylsilyloxy)-2-methyl-3-buten-4-yl>-2-thiophenecarboxylate
  参考文献：
  名称：

  Design and synthesis of novel FKBP inhibitors

  摘要：

  Small molecule FKBP inhibitors were prepared with inhibitory activity ranging from micromolar to nanomolar. The design of these inhibitors derives from a structural analysis of the substrates for FKBP and cyclophilin. As a consequence of this analysis two key observations were made, namely: (1) amino ketone moieties are suitable as FKBP recognition elements at the P1-P1' site and (2) the P3'-P4' site will accept a trans-olefin as a suitable mimetic of a peptide moiety. The preparation of these non-peptide inhibitors is readily accomplished by a protocol which includes the synthesis of chiral propargylic amines and their subsequent conversion into vinyl zirconium reagents.

  DOI：

  10.1021/jm00101a005
• 作为产物：
  描述：

  2-噻吩甲醛 、 (S)-(-)-(3-hydroxy-2-methylpropyl)triphenylphosphonium bromide 在 苯基锂 作用下， 生成 (E,2R)-2-methyl-4-thiophen-2-ylbut-3-en-1-ol
  参考文献：
  名称：

  Design and synthesis of novel FKBP inhibitors

  摘要：

  Small molecule FKBP inhibitors were prepared with inhibitory activity ranging from micromolar to nanomolar. The design of these inhibitors derives from a structural analysis of the substrates for FKBP and cyclophilin. As a consequence of this analysis two key observations were made, namely: (1) amino ketone moieties are suitable as FKBP recognition elements at the P1-P1' site and (2) the P3'-P4' site will accept a trans-olefin as a suitable mimetic of a peptide moiety. The preparation of these non-peptide inhibitors is readily accomplished by a protocol which includes the synthesis of chiral propargylic amines and their subsequent conversion into vinyl zirconium reagents.

  DOI：

  10.1021/jm00101a005